Forget ‘Big Pharma’, my money’s on this smoking hot small-cap stock

Here’s one biotech business that really could be worth the risk.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many investors are attracted to large pharmaceutical companies for the relative certainty of earnings and high dividends. Think GlaxonSmithKline and AstraZeneca.

However, those willing to embrace more risk for the prospect of sizeable capital gains should look further down the market spectrum. One small cap that’s grabbed my attention in recent weeks has been Motif Bio (LSE: MTB) — a dual-listed biotech company (listed on NASDAQ as well as AIM) focused on tackling superbugs that have developed resistance to existing antibiotics.  

You may not have heard of the business before but last week’s news that Iclaprim, a treatment designed for combat acute bacterial and skin structure infections, has made it through the first of two large Phase 3 trials (REVIVE-1) means it should start hitting many investors radars over the next few months. Here’s what you need to know.

Seriously undervalued

Passing through a Phase 3 trial — the final stage in clinical testing — isn’t easy. Required by regulators before a new treatment can be marketed, many companies fail to get this far, underlining how risky investing in biotech stocks can sometimes be. Here, Motif Bio bucks the trend.

REVIVE-1 demonstrated that Iclaprim met two desired end points. First, it delivered early clinical response by reducing the size of skin lesions by at least 20% in 48-72 hours after starting the course of antibiotics. Secondly, it met test of cure targets after patients showed an improvement in the 7-14 days following the completion of treatment.

It gets better. Results suggested that Iclaprim was as effective as Vancomycin, one of the leading treatments currently used. What’s more, any side effects were deemed mild and clinically irrelevant. The knockout punch, however, is that Iclaprim is safe to use with those who have bacterial skin infections and kidney disease, something that can’t be said for its competitor. So, what happens next?

Assuming all goes to plan (results from the identical REVIVE-2 trial are expected in the second half of the year), Motif will file a new drug application to the US Food and Drug Administration in the first half of 2018. A Marketing Authorisation Application will also be finding its way to the European Medicines Agency around the same time. The company hopes to receive approval on both fronts before the end of 2018.

Although CEO Graham Lumsden remains fairly tight-lipped on the matter, there’s also the possibility of the company announcing news concerning licencing deals over the next few weeks, along with details on funding for REVIVE-2.

Multi-bagger in the making?

Right now, Motif Bio has a market cap of just £76m. That’s after the 60% rise in its share price since the end of March and announcement of REVIVE-1 results. It’s also substantially less than valuations attached to industry peers such as Paratek (market cap just short of $600m). While short term traders will come and go, the eventual adoption of Iclaprim in hospitals — generating $1bn of annual revenues in the US alone — could lead to substantial profits for long-term holders.

Of course, buying small-cap companies — even those offering significant upside — still requires patience and a willingness to tolerate volatility. Although I’ve backed the company to succeed (and some brokers now have target prices of 125p), it’s essential that prospective investors consider their willingness to tolerate capital risk before taking the leap.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers owns shares of Motiv Bio. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 reasons why I’m loading up on FTSE 100 shares

This Fool thinks FTSE 100 shares look cheap. With that, he plans to continue snapping them up today. Here's one…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Why wait? I’d buy FTSE 100 shares now before the next stock market rally!

Our writer explains why he'd snap up what he sees as bargain FTSE 100 shares now rather than waiting in…

Read more »

Investing Articles

Is it time for me to change my tune about Rolls-Royce shares?

This Fool has steered clear of buying Rolls-Royce shares. But after its recent performance, he's reconsidering his stance. Here's why.

Read more »

Investing Articles

Aviva share price: 3 reasons to consider buying for 2024

The Aviva share price is still lower then when I bought some nearly a decade ago. Here's why I'm thinking…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

These 2 shares could bank me £328 a month in second income

Jon Smith runs through two FTSE stocks that have above-average dividend yields that could pay out a generous second income…

Read more »

Stack of one pound coins falling over
Investing Articles

This passive income plan is simple – but could earn me thousands!

Christopher Ruane explains how putting a fiver a day to work in the stock market might help him earn thousands…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Charticle

After record profits, are Lloyds shares a buy, sell, or hold?

As Lloyds pulls in pre-tax profits of £7.5bn, boosts its dividend, and continues to repurchase shares, are the company’s shares…

Read more »

Investing Articles

NatWest shares: is a once-in-a-lifetime opportunity on the way?

Should investors get ready for a unique opportunity as the UK government plans to sell off its NatWest shares later…

Read more »